26541-51-5

Basic information

• Product Name: N-NITROSOTHIOMORPHOLINE
• Synonyms: N-NITROSOTHIOMORPHOLINE;4-Nitrosothiomorpholine
• CAS NO: 26541-51-5
• Molecular Formula: C₄H₈N₂OS
• Molecular Weight: 132.18
• Mol File: 26541-51-5.mol
• Article Data: 10

Chemical Properties

• Melting Point: 35-37 °C
• Boiling Point: 303.8°Cat760mmHg
• Flash Point: 137.5°C
• Appearance: /
• Density: 1.183 (estimate)
• Vapor Pressure: 0.00163mmHg at 25°C
• Refractive Index: 1.6430 (estimate)
• PKA: -5.00±0.20(Predicted)
• CAS DataBase Reference: N-NITROSOTHIOMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-NITROSOTHIOMORPHOLINE(26541-51-5)
• EPA Substance Registry System: N-NITROSOTHIOMORPHOLINE(26541-51-5)

Safety Data

• Hazardous Substances Data: 26541-51-5(Hazardous Substances Data)

Usage

Safety Profile

Questionable carcinogen with experimental carcinogenic data.Mutation data reported. When heated to decomposition it emits very toxic fumes of NOx and SOx.

InChI:InChI=1/C4H8N2OS/c7-5-6-1-3-8-4-2-6/h1-4H2

Upstream product

• 123-90-0 Thiomorpholin 
• 80-11-5 N-methyl-N-nitrosotoluene-p-sulfonamide 
• 67809-83-0 S-nitroso-N-acetylpenicillamine 

Downstream Products

• 5997-01-3 4-amino-tetrahydro-2H-1,4-thiazine 

Relevant articles and documents

Visible-Light-Induced Photoaddition of N-Nitrosoalkylamines to Alkenes: One-Pot Tandem Approach to 1,2-Diamination of Alkenes from Secondary Amines

The generation of aminium radical cation species from N-nitrosoamines is disclosed for the first time through visible-light excitation at 453 nm. The developed visible-light-promoted photoaddition reaction of N-nitrosoamines to alkenes was combined with the o-NQ-catalyzed aerobic oxidation protocol of amines to telescope the direct handling of harmful N-nitroso compounds, where the desired α-amino oxime derivatives were obtained in a one-pot tandem N-nitrosation and photoaddition sequence.

Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria

We previously discovered a series of novel biaryloxazolidinone analogues bearing a hydrazone moiety with potent antibacterial activity. However, the most potent compound OB-104 exhibited undesirable chemical and metabolic instability. Herein, novel biaryloxazolidinone analogues were designed and synthesized to improve the chemical and metabolic stability. Compounds 6a-1, 6a-3, 14a-1, 14a-3 and 14a-7 showed significant antibacterial activity against the tested Gram-positive bacteria as compared to radezolid and linezolid. Further studies indicated that most of them exhibited improved water solubility and chemical stability. Compound 14a-7 had MIC values of 0.125–0.25 μg/mL against all tested Gram-positive bacteria, and showed excellent antibacterial activity against clinical isolates of antibiotic-susceptible and antibiotic-resistant bacteria. Moreover, it was stable in human liver microsome. From a safety viewpoint, it showed non-cytotoxic activity against hepatic cell and exhibited lower inhibitory activity against human MAO-A compared to linezolid. The potent antibacterial activity and all these improved drug-likeness properties and safety profile suggested that compound 14a-7 might be a promising drug candidate for further investigation.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.